Vice-Rector for the scientific block of KazNMU

Kairat Davletov

Professor Kairat Davletov graduated from Kazakh National Medical University in Almaty, Kazakhstan, in 1986, and worked as a cardiologist at the Republican Research Institute of Cardiology and Internal Diseases until 1990. He then moved to the National Medical Research Center of Cardiology in Moscow, Russian Federation, where he completed his doctoral thesis on cardiology in 1994. After returning to Almaty, he worked for the Ministry of Education, Culture and Health, and later for the National Centre of Healthy Lifestyle. In 2004, he graduated from the Rollins School of Public Health at Emory University (United States of America) with a Master of Public Health degree. After graduation, Dr Davletov worked for the American International Health Alliance and the United States Agency for International Development (USAID) Central Asia Regional Health Office in Almaty. In 2013, he rejoined the Republican Research Institute of Cardiology and Internal Diseases in Almaty as Deputy Director. In 2016, he moved to Kazakh National Medical University as Dean of the School of Public Health, but later decided to devote more time to research. Since 2019, he has been Director of the Health Research Institute at Al-Farabi Kazakh National University. Since October 2020 he rejoined Kazakh National medical University as a prorector for research.

He is a member of the European Public Health Association, the European Society of Cardiology and the European Atherosclerosis Society.

Contributions to Science

  1. My main research interest is regional and ethnic disparities and mortality analysis in the country in relation to behavioral risk factors.  The results of our research indicate that alcohol consumption is the main determinant of premature CVD and overall mortality in the country. My recent publications address high levels of premature cardiovascular mortality in Kazakhstan. We found substantial differences in CVD and all-cause mortality across the regions, as well as between ethnic groups, both among males and females and in rural/urban areas.  These differences are most pronounced in the age group 20-59.  Information on self-reported alcohol consumption and regional alcohol sales show consistently higher rates of alcohol consumption and smoking among ethnic Russians, both in women and men and across all adult age groups.
  1. Regional differences in cardiovascular mortality in Kazakhstan: further evidence for the ‘Russian mortality paradox’? The European Journal of Public Health 25 (5), 890-894
  2. Ethnic differences in all-cause mortality rates in Kazakhstan. Public Health, 2016, 133, 57-62
  1. Alcohol control policies in Former Soviet Union countries: A narrative review of three decades of policy changes and their apparent effects. Drug and Alcohol Review, 2021, 40(3), стр. 350–367
  1. In addition, with a team of collaborators of GBD, I contributed to the GBD study by providing data, participating in data analysis and results interpretation for Kazakhstan and former Soviet Union countries for behavioral, environmental, occupational and metabolical risks by the GBD projects. The GBD study quantifies, on an annual basis, the magnitude of health loss at global, national, and regional levels, and does so by age, sex, and population. I was the first GBD collaborator from Kazakhstan and Central Asia and the first one who received a GBD scholarship for their annual training in Greece in 2018.
  1. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020. Bryazka, D. et al, The Lancet, 2022, 400(10347),
  2. Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019. Ward, J.L. et al, The Lancet, 2021, 398(10311)
  3. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Reitsma, al. The Lancet, 2021, 397(10292)

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 2020.;

  1. Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. //New England Journal of Medicine, V-379, Issue-25, December, 2018
  1. I also contributed to the NCD risk factors collaboration study by providing the data, participating in the data analysis and results interpretation for the three regions of Kazakhstan where my team the first time in the country conducted a STEPS-like survey. The study examined a random sample of 1,500 men and women in each region to assess basic risk factors according to WHO/STEPS methodology. We found significant regional and ethnic differences in the prevalence of risk factors across the country.
  1. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight. Iurilli, M.L.C. et al. eLife, 2021, 10, e60060
  2. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128,9 million children, adolescents, and adults. The Lancet, V.309, 2020
  3. Repositioning of the global epicentre of non-optimal cholesterol. Nature582, 73–77 (2020).
  4. Rising rural body-mass index is the main driver of the global obesity epidemic in adults. Nature569, 260–264 (2019).
  1. As a Principal Investigator in the country for the EUROASPIRE IV and V study, I initiated and organized the first multi-centered international study in Kazakhstan.  EUROASPIRE is a famous study funded by the European Society of Cardiology that aims to determine whether the clinical practice achieved the standards set in the CVD prevention guidelines.  We found a high prevalence of uncontrolled risk factors and low coverage by lipid-lowering and AH drugs of patients in high-risk primary care patients, low adherence to treatment and insufficient therapeutic control of blood pressure, LDL-cholesterol and glycemic control.  As a National CVD prevention coordinator, I participated in the 2016 European Guidelines for CVD prevention in clinical practice.
  1. Alcohol consumption patterns across Europe and adherence to the European guidelines in coronary patients: Findings from the ESC-EORP EUROASPIRE V survey. Atherosclerosis, 2020
  2. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. European Journal of Preventive Cardiology, 2020.
  3. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis.
  4. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27

countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European Journal of Preventive Cardiology, 2019.

  1. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology EUROASPIRE IV cross-sectional survey in fourteen European regions.

European Journal of Preventive Cardiology, 2016, 1-12.

  1. 2016 European Guidelines for CVD prevention in clinical practice,

European Heart Journal, May 2016, 1-78.

  1. Initiated and served as a local PI for two PHRI-funded studies: PURE and INVICTUS clinical trials. PURE is the famous prospective epidemiological study conducted in 27 countries on four continents of the world and led by professor Salim Yusuf, our sub-study is the first multi-centered cohort study in Kazakhstan. INVICTUS is a randomized clinical trial that has enrolled 4565 patients from 138 sites in 23 countries from Africa, Asia and South America. Registered at NCT02832544
  2. Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. The Lancet, V.396, 2020
  3. The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. American Heart Journal, 2020.
  4. During my work at the Russian Cardiology Center, in Moscow, Russia I studied the relationship between the processes of thrombosis and different degrees of atherosclerosis. We have shown that 1) the highest D-dimer level was observed in patients with atherosclerosis lesions in two or more areas and peripheral artery disease, 2) elevated D-dimer and low platelet aggregation are independent predictors of thrombotic events in patients with peripheral artery disease. These observations suggest that intravascular thrombus formation correlates with the extent of atherosclerosis.
  5. D-dimer and fibrinolysis in patients with various degrees of atherosclerosis. E. Panchenko, A. Dobrovolsky, K. Davletov, , E. Titaeva, A. Kravets, Y. Podinovskaya and Y. Karpov.

European Heart Journal (1995) 16, 38-42

  1. D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease. A. L. Komarov, E. P. Panchenko, A. B. Dobrovolsky, Yu. A. Karpov, A. D. Deev, E. V. Titaeva, K. K. Davletov, A. R. Eshkeeva and L. A. Markova. European Heart Journal (2002) 23, 1309–1316

Complete List of Published Work in MyBibliography:,15631158